<DOC>
	<DOC>NCT01100151</DOC>
	<brief_summary>The purpose of this study is to assess the safety and tolerability of RDC-1036 (ALKS 37) in adults with opioid-induced constipation (OIC) following repeat dose administration</brief_summary>
	<brief_title>ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)</brief_title>
	<detailed_description>Approximately 60 subjects will be enrolled in 1 of 2 cohorts. Following a review of Cohort 1 safety and tolerability data, subjects will then be enrolled into Cohort 2, to explore additional doses. Dose escalation will occur in both cohorts. There will be 18 visits over a 6-week period.</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<criteria>18 to 70 years of age Body mass index (BMI) of 19 to 35 kg/m2 at screening Receiving prescribed opioid medication for the management of chronic, noncancer, pain Diagnosis of opioidinduced constipation (OIC) Willingness to stop all laxatives and other bowel regimens from the first study visit following screening until the end of the study. The use of constipation rescue medication will be allowed during the study. Pregnancy and/or currently breastfeeding Clinically significant medical condition or illness (other than the condition for which the pain medication is being prescribed) Receiving treatment with opioid therapy for cancerrelated pain, abdominal pain, scleroderma, and/or for the management of drug addiction Any gastrointestinal (GI) or pelvic disorder known to affect bowel transit, produce a GI obstruction, or contribute to bowel dysfunction other than opioidinduced constipation (eg, diverticulitis, other intestinal strictures, bezoars) Use of medical devices such as pacemakers, infusion pumps, or insulin pumps Use of naloxone, Subutex or Suboxone, Revia, Relistor, or Entereg starting 15 days before the first study visit following screening until the end of the study Participation in a clinical trial of a pharmacological agent within 30 days before screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Opioid-induced constipation</keyword>
	<keyword>RDC-1036</keyword>
	<keyword>ALKS 37</keyword>
</DOC>